中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
Black porous silicon as a photothermal agent and immunoadjuvant for efficient antitumor immunotherapy

文献类型：期刊论文

作者Xu, Wujun7; Pang, Cui5,8; Song, Chaojun6; Qian, Jing4,7; Feola, Sara3; Cerullo, Vincenzo3; Fan, Li8; Yu, Haijun1,2; Lehto, Vesa-Pekka7
刊名ACTA BIOMATERIALIA
出版日期2022-10-15
卷号152页码:473-483
ISSN号1742-7061
关键词Photothermal therapy Chemotherapy Immunotherapy Cancer Adjuvant
DOI10.1016/j.actbio.2022.08.073
通讯作者Xu, Wujun(wujun.xu@uef.fi) ; Fan, Li(xxfanny@fmmu.edu.cn) ; Lehto, Vesa-Pekka(vesa-pekka.lehto@uef.fi)
英文摘要Photothermal therapy (PTT) in combination with other treatment modalities has shown great potential to activate immunotherapy against tumor metastasis. However, the nanoparticles (NPs) that generate PTT have served as the photothermal agent only. Moreover, researchers have widely utilized highly immuno-genic tumor models to evaluate the immune response of these NPs thus giving over-optimistic results. In the present study black porous silicon (BPSi) NPs were developed to serve as both the photothermal agent and the adjuvant for PTT-based antitumor immunotherapy. We found that the poorly immunogenic tumor models such as B16 are more valid to evaluate NP-based immunotherapy than the widely used im-munogenic models such as CT26. Based on the B16 cancer model, a cocktail regimen was developed that combined BPSi-based PTT with doxorubicin (DOX) and cytosine-phosphate-guanosine (CpG). BPSi-based PTT was an important trigger to activate the specific immunotherapy to inhibit tumor growth by featuring the selective upregulation of TNF-alpha. Either by adding a low dose DOX or by prolonging the laser heating time, a similar efficacy of immunotherapy was evoked to inhibit tumor growth. Moreover, BPSi acted as a co-adjuvant for CpG to significantly boost the immunotherapy. The present study demonstrates that the BPSi-based regimen is a potent and safe antitumor immunotherapy modality. Moreover, our study high-lighted that tuning the laser heating parameters of PTT is an alternative to the toxic cytostatic to evoke immunotherapy, paving the way to optimize the PTT-based combination therapy for enhanced efficacy and decreased side effects.
WOS关键词NANOPARTICLES ; THERAPY ; ANTIGEN ; BIOCOMPATIBILITY ; DELIVERY ; CHITOSAN
资助项目Academy of Finland[314412] ; National Natural Science Foundation of China[82171962] ; Key reseach and Development Program of Science and Technology Department of Shaanxi Province[2022ZDLSF01-03] ; China Scholarship Council
WOS研究方向Engineering ; Materials Science
语种英语
出版者ELSEVIER SCI LTD
WOS记录号WOS:000869993100002
源URL[http://119.78.100.183/handle/2S10ELR8/303103]  
专题中国科学院上海药物研究所
通讯作者Xu, Wujun; Fan, Li; Lehto, Vesa-Pekka
作者单位1.Chinese Acad Sci, Shanghai Inst Mat Med, Ctr Pharmaceut, Shanghai 201203, Peoples R China
2.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
3.Univ Helsinki, Fac Pharm, Helsinki 00014, Finland
4.Lanzhou Univ, Coll Chem & Chem Engn, Lanzhou 730000, Peoples R China
5.Air Force Hosp Eastern Theater PLA, Dept Oncol, Nanjing 210001, Peoples R China
6.Northwestern Polytech Univ, Sch Life Sci, Xian 710032, Peoples R China
7.Univ Eastern Finland, Dept Appl Phys, Kuopio 70211, Finland
8.Airforce Med Univ, Dept Pharmaceut Chem & Anal, 169th Changle West Rd, Xian 710032, Shaanxi, Peoples R China
推荐引用方式
GB/T 7714		 Xu, Wujun,Pang, Cui,Song, Chaojun,et al. Black porous silicon as a photothermal agent and immunoadjuvant for efficient antitumor immunotherapy[J]. ACTA BIOMATERIALIA,2022,152:473-483.
APA Xu, Wujun.,Pang, Cui.,Song, Chaojun.,Qian, Jing.,Feola, Sara.,...&Lehto, Vesa-Pekka.(2022).Black porous silicon as a photothermal agent and immunoadjuvant for efficient antitumor immunotherapy.ACTA BIOMATERIALIA,152,473-483.
MLA Xu, Wujun,et al."Black porous silicon as a photothermal agent and immunoadjuvant for efficient antitumor immunotherapy".ACTA BIOMATERIALIA 152(2022):473-483.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。